18:57 , Oct 27, 2017 |  BC Week In Review  |  Company News

Daiichi and MD Anderson partner to develop AML candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and the University of Texas MD Anderson Cancer Center (Houston, Texas) partnered to develop multiple therapies for acute myelogenous leukemia (AML). During the multiyear collaboration, MD Anderson is to conduct...
15:24 , Aug 14, 2017 |  BC Extra  |  Preclinical News

Papers uncover predictive markers for BET inhibitor responses

A trio of papers published in Nature Medicine today challenge the notion that similar mutations in the same gene can predict the same drug responses across different types of cancer. While two separate teams of...
15:21 , Mar 21, 2017 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis In vitro and mouse studies identified a chlorobenzamide-based inhibitor of bromodomain 1 of BET bromodomain proteins that could help treat colitis. Structure-based design, chemical synthesis and in vitro competitive bromodomain binding assays on hits...
22:25 , Mar 9, 2017 |  BC Innovations  |  Product R&D

Double your pleasure

SignalRx Pharmaceuticals Inc. has developed an in silico platform for designing small molecule dual inhibitors that is more targeted and efficient than the standard approach of experimentally screening vast chemical libraries to find a molecule...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BET bromodomain proteins; bromodomain containing 2 (BRD2); BRD3; BRD4; von Hippel-Lindau tumor suppressor (vHL)

Cancer INDICATION: Prostate cancer Cell culture and mouse studies identified a BET bromodomain protein degrader that could help treat castration-resistant prostate cancer (CRPC). Chemical synthesis and testing in three human CRPC cell lines of small molecules linking...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Tensha Therapeutics, Roche deal

Roche will acquire Tensha for $115 million in cash plus up to $420 million in undisclosed clinical and regulatory milestones. Tensha’s TEN-010, a small molecule bromodomain inhibitor that is selective for the bromodomain and...
02:45 , Jan 12, 2016 |  BC Extra  |  Company News

Roche BETs on Tensha

Roche (SIX:ROG; OTCQX:RHHBY) will acquire Tensha Therapeutics Inc. (Cambridge, Mass.) for $115 million in cash up front. Tensha shareholders are eligible for $420 million in milestones. The pharma will gain Tensha's TEN-010, a small molecule...
07:00 , Oct 8, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); BET bromodomain proteins

Cancer INDICATION: Acute myelogenous leukemia (AML) Studies in mice and patient samples suggest inhibiting the Wnt/CTNNB1 pathway could help treat BET bromodomain protein inhibitor-resistant AML. In BET inhibitor-resistant AML cells from patients, expression of Wnt/CTNNB1 pathway target...
07:00 , Jul 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BET bromodomain proteins; bromodomain containing 2 (BRD2); BRD3; BRD4; myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX)

Cancer INDICATION: Leukemia In vitro studies suggest a new class of BET bromodomain protein inhibitors could help treat MLL-mutant leukemias. Chemical synthesis and in vitro testing of tricyclic pyridoindole analogs identified a compound that selectively bound BRD2,...
08:00 , Jan 5, 2015 |  BioCentury  |  Product Development

BETting early

Index Ventures-backed oncology play Oncoethix S.A. traded potentially larger returns for a faster clinical program for the company's primary asset when the Phase II program became too big for the small biotech to handle. On...